2014
AI-09PATTERNS OF SALVAGE TREATMENT FOR HIGH GRADE GLIOMA IN THE TEMOZOLOMIDE ERA
Escorcia F, Folkert M, Spratt D, Zumsteg Z, Chan T, Omuro A, Beal K, Gutin P, Yamada J. AI-09PATTERNS OF SALVAGE TREATMENT FOR HIGH GRADE GLIOMA IN THE TEMOZOLOMIDE ERA. Neuro-Oncology 2014, 16: v3-v3. PMCID: PMC4217875, DOI: 10.1093/neuonc/nou238.9.Peer-Reviewed Original ResearchHigh-grade gliomasSalvage radiation therapyTreatment-related factorsTrimodality therapyRadiation therapySalvage chemotherapyHazard ratioOverall survivalGrade gliomasOnly treatment-related factorOptimal salvage therapyKaplan-Meier methodCox regression modelingGrade IV patientsLarge retrospective seriesConfidence intervalsSalvage therapyTrimodality treatmentBilateral diseaseInitial surgeryRecurrent diseaseSalvage surgerySalvage treatmentIV patientsConsecutive patients
2008
Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)
Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ, investigators O. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). European Journal Of Cancer 2008, 44: 1210-1216. PMID: 18248979, DOI: 10.1016/j.ejca.2007.12.005.Peer-Reviewed Original ResearchConceptsProgression-free survivalCentral pathology reviewOverall survivalAnaplastic astrocytomaMonths 95Pathology reviewAA patientsGlioblastoma multiformeConfidence intervalsPrevious phase III trialsMedian overall survivalPhase III studyPhase III trialsGrade 3 tumorsLonger overall survivalTotal treatment durationAdjuvant chemotherapyEORTC studyAdjuvant regimenIII studyIII trialsImproved survivalTreat analysisPathological assessmentBCNU chemotherapy